講演情報
[O-24]QUASAR長期継続試験の140週までの潰瘍性大腸炎に対するグセルクマブの有効性および安全性
*久松 理一1、Laurent Peyrin-Biroulet2、Brian Bressler3、Axel Dignass4、Bruce E. Sands5、Yelina Alvarez6、Thomas Baker6、Nicole Shipitofsky6、Ye Miao6、Hongyan Zhang6、佐々木 絢子6、Gary R. Lichtenstein7、David T. Rubin8、Jessica R. Allegretti9 (1. 杏林大学医学部 消化器内科学、2. Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine、3. University of British Columbia、4. Department of Medicine I, Agaplesion Markus Hospital, Goethe University、5. Icahn School of Medicine at Mount Sinai、6. J&J Innovative Medicine、7. University of Pennsylvania School of Medicine、8. University of Chicago Medicine Inflammatory Bowel Disease Centre、9. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School)
